Uremic encephalopathy
Conditions
Interventions
Hemodialysis: Enhanced HDF:Dialysis parameters: dialysate flow rate 500 mL/min, blood flow rate 150–300 mL/min, temperature 36.5°C. Anticoagulation: Enoxaparin sodium (non-bleeding risk) or nafamost
Hemodialysis: High volume HDF:High-Volume HDF Group:
Parameters: Bicarbonate dialysate (Na+ 140 mmol/L, Ca2+ 1.5 mmol/L, K+ 2 mmol/L), blood flow 200–300 mL/min, dialysate flow 800 mL/min, post-di
>=3 sessions/week for 2 weeks.
Hemodialysis: Hemodialysis + hemoperfusion: Protocol: Hemoperfusion cartridge connected in series with the dialyzer. After 2 hours, the cartridge is removed, and HD continues for 2 hours (total 4 hou
Peritoneal dialysis: APD enhancement:Device: Baxter automated PD system (USA). Dialysis fluid: 1.5% or 2.5% lactate-based solution (Na+ 132 mmol/L, Cl- 96 mmol/L, Ca2+ 1.25/1.75 mmol/L, Mg2+ 0.25 mmo
Sponsors
NingXia Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Maintenance hemodialysis or peritoneal dialysis for >3 months. 2. Diagnosis of uremic encephalopathy. 3. Provision of informed consent.
Exclusion criteria
Exclusion criteria: 1. Age <18 years. 2. History of alcohol or substance abuse/dependence within the past year. 3. Other metabolic encephalopathies (e.g., hepatic encephalopathy, pulmonary encephalopathy, diabetic ketoacidosis, drug-induced encephalopathy). 4. Dialysis-related neurological disorders (e.g., dialysis disequilibrium syndrome, dialysis dementia, Wernicke’s encephalopathy). 5. Acute cerebral infarction, significant cerebral atrophy, or severe psychiatric disorders. 6. Use of psychotropic medications within 1 month prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of uremic encephalopathy treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Small molecular toxins (creatinine, urea, K, Na, Cl);medium molecular toxins (ß2-MG levels, parathyroid hormone);protein binding compounds (p-cresol sulfate, indolic acid, homocysteine) ;blood gas analysis; | — |
Countries
China
Contacts
Public ContactTian Na
NingXia Medical University
Outcome results
None listed